News >

Gene Expression Model Predicts PFS in Follicular Lymphoma

Jason Harris
Published: Tuesday, Feb 27, 2018

Gilles A. Salles, MD, PhD

Gilles A. Salles, MD, PhD
A “robust” 23-gene expression-based model successfully predicted progression-free survival (PFS) for patients with follicular lymphoma enrolled in the phase III randomized PRIMA trial.

“Despite recent progress in the stratification and management of patients with follicular lymphoma, a substantial proportion of patients are still underserved by existing standard treatment and have rapid progression of their disease,” wrote Salles et al. “Our gene-expression predictor could be valuable in the clinical setting to identify patients at high risk or low risk of progression so as to adjust the therapeutic strategy and enrollment for innovative treatments.”
Huet S, Tesson B, Jais JP, et al. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts [published online February 20, 2018]. Lancet Oncol. doi: 10.1016/S1470-2045(18)30102-5.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesNov 29, 20192.0
Advances in™ ALL: The Role of T-Cell Engaging Immunotherapy in Treating Relapsed DiseaseNov 30, 20191.0
Publication Bottom Border
Border Publication